$EIKN

Eikon Therapeutics (EIKN) appointed Dr. Ching-Pin Chang as Executive VP & Chief Scientific Officer. Chang has extensive experience in cardiovascular research and drug discovery. The company focuses on oncology with several clinical-stage drug candidates. EIKN shares are down 1.49% at $11.21.

Eikon Therapeutics (NASDAQ:EIKN) is developing PARP1 inhibitors EIK1003 and EIK1004, targeting cancer treatments. EIK1003 is being tested in combinations with paclitaxel, carboplatin, and abiraterone. EIK1004 is designed for brain penetration. The company also has EIK1005, a Werner helicase inhibitor, in early studies. Eikon aims to address unmet medical needs in oncology.

Eikon Therapeutics filed an 8-K to provide an updated corporate presentation and clinical updates. For EIK1001 (TLR7/8) TeLuRide-005, fully enrolled, NSCLC ORR was 63.1% with median DOR over 11 months as of May 4, 2026, and Grade ≥3 drug-related TRAEs were 48.6%. EIK1003 showed ORR 14.3% (monotherapy) and 24.5% (combo).

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates • Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology

Eikon Therapeutics (Nasdaq: EIKN) said its independent Data Monitoring Committee recommended continuing the TeLuRide-006 adaptive Phase 2/3 trial of EIK1001 in advanced melanoma and selecting 0.60 mg/m2 as the single dose for patients randomized to EIK1001. The dose follows a prespecified analysis of unblinded data.

Eikon Therapeutics (Nasdaq: EIKN) said it added Johnny Bennett, Ph.D. to its Scientific Advisory Board. Bennett is Vice President and Head of Discovery Chemistry at Merck Research Laboratories. Eikon noted Merck has supplied KEYTRUDA (pembrolizumab) for registration-enabling trials for EIK1001 and supported early combinations with EIK1005, and participated in Eikon’s IPO.

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc.

Baker Hughes reported Q2 earnings of 64 cents per share, which it said beat analyst consensus of 50 cents, and quarterly sales of $6.742 billion versus $6.523 billion expected. The stock rose 8.2% to $61.97 on Monday. The article also notes broad gains in U.S. equities.

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001861123 false 0001861123 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,

BlackRock Portfolio Management LLC has disclosed a passive investment in Eikon Therapeutics, Inc. (EIKN), holding 3,002,737 shares, which represents 5.5% of the company's common stock. This Schedule 13G filing indicates a beneficial ownership for passive purposes, with BlackRock exercising sole voting power for 2,939,120 shares and sole dispositive power for all 3,002,737 shares. The disclosure clarifies that these holdings are attributed to specific BlackRock business units and do not signify an intent to influence control over Eikon Therapeutics.